UNASSIGNED: 4147 Background: @entity1 (Pts) with localized @entity418 were evaluated for @entity137 , operative mortality/morbidity, and overall survivorship in a regimen that did NOT contain radiation therapy. METHODS: Pts with T3N1M0 @entity418 confirmed by endoscopic ultrasound and CAT scan were eligible for this study. Our therapy consisted of combined @entity900 100 mg/m(2), @entity1311 ( @entity1311 ) 125mg/ m(2), @entity10049 ( @entity10049 ) 150 mg /Kg or 80 mg/Kg, and @entity4181 500mg /m(2). Chemotherapy was given for 16 weeks prior to surgery. Adjuvant chemotherapy was administered for the @entity1 whose pathology at the time of the surgery demonstrated microscopic disease. RESULTS: 33 pts (29 males, 4 females) with @entity420 (n=30) or @entity957 (n=3) were enrolled. 26 pts (78%) were symptomatic with @entity1282 at the time of enrollment on the study. 28 pts completed two cycles of neoadjuvant chemotherapy, 19 (68%) showed improvement of @entity1282 . There were 9 instances of grade 3 or 4 hematological @entity137 . There were 11 instances of non-hematological grades 3-4 @entity137 : fatigue (4), @entity390 (1) @entity294 (2) and @entity3136 (4). Of 33 R0 resections, 5(15%) had no gross disease, 2 (6%) had no microscopic @entity66 . Major surgical complication occurred in 5(15%) of 33 pts. Operative mortality was 1 of 33 pts. CONCLUSIONS: Our regimen of preoperative and postoperative chemotherapy without radiation for @entity418 has produced a rapid relief of @entity1282 , acceptable @entity137 and durable response rates. No @entity1 developed local recurrence, however, 14 pts developed distant @entity3 , the sites included: 1 rectum and mediastinal lymph node, 2 brain, 2 liver and lung, 1 liver and spleen, 3 bone, 4 liver, lung, and brain, and 1 lung. Seventeen pts died after being followed for a median of 12 months (range 2 to 43 months), while 16 others remain alive with median follow up of 39 months (range 5 to 60 months). Median survival was estimated to be 42 months with a 95% lower confidence bound of 14 months. The Kaplan-Meier estimates of 1- and 3-year survival were 75% (95%CI: 60-90%) and 50% (95%CI: 32 to 68%). No significant financial relationships to disclose.

Phase II neoadjuvant and adjuvant chemotherapy for localized XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['Leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['Cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Paclitaxel', 'Taxol'] @entity10049 :: ('MESH:D005467', 'Chemical') :: ['Fluorodeoxyuridine', 'FUdR'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal carcinoma'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity418 :: (MESH:D004938,Disease) :: ['esophageal carcinoma']
